Franklin Street Advisors Inc. NC Raises Stock Position in Kenvue Inc. (NYSE:KVUE)

Franklin Street Advisors Inc. NC increased its stake in Kenvue Inc. (NYSE:KVUE) by 8.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 210,597 shares of the company’s stock after buying an additional 16,580 shares during the period. Franklin Street Advisors Inc. NC’s holdings in Kenvue were worth $4,534,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Clearstead Advisors LLC purchased a new position in Kenvue during the third quarter valued at $25,000. Planned Solutions Inc. purchased a new position in Kenvue during the 4th quarter valued at about $27,000. EverSource Wealth Advisors LLC bought a new stake in Kenvue during the third quarter worth about $28,000. AdvisorNet Financial Inc purchased a new stake in Kenvue in the third quarter worth about $28,000. Finally, Global Retirement Partners LLC bought a new position in shares of Kenvue during the third quarter valued at approximately $28,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on KVUE. Royal Bank of Canada dropped their price target on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. UBS Group lifted their price target on Kenvue from $20.00 to $23.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 19th. The Goldman Sachs Group initiated coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective on the stock. Finally, JPMorgan Chase & Co. decreased their target price on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 9th. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $25.42.

Kenvue Trading Up 0.0 %

Shares of KVUE stock opened at $21.46 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. The firm’s 50 day moving average is $20.01 and its 200 day moving average is $20.25. Kenvue Inc. has a 12-month low of $17.82 and a 12-month high of $27.80.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The firm had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. The firm’s revenue for the quarter was down 2.7% on a year-over-year basis. On average, equities analysts expect that Kenvue Inc. will post 1.17 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were given a dividend of $0.20 per share. The ex-dividend date was Tuesday, February 13th. This represents a $0.80 annualized dividend and a yield of 3.73%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.